The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1718
December 23, 2024
View Complete Issue         Table of Contents 2019 
Crexont — Extended-Release Carbidopa/Levodopa for Parkinson's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Crexont — Extended-Release Carbidopa/Levodopa for Parkinson's Disease
December 23, 2024 (Issue: 1718)
The FDA has approved Crexont (Amneal), an extended-release capsule formulation of carbidopa/levodopa, for treatment of Parkinson's disease (PD), postencephalitic parkinsonism, and parkinsonism associated with carbon monoxide or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Crexont — Extended-Release Carbidopa/Levodopa for Parkinson's Disease
Article code: 1718e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.